Survival rates lower in stage III inflammatory breast cancer than in non-inflammatory cancer

Embargoed until: Publicly released: 2026-04-10 01:00

International

CC-0

International scientists say survival rates among people with stage III inflammatory breast cancer (IBC) are worse than for stage III non-inflammatory breast cancer (non-IBC), whatever the subtype of tumour. The team looked at treatment and outcomes among 47,702 US breast cancer patients, finding that patients with IBC were more likely to die from the cancer or from other causes than those with non-IBC. They also looked at treatment using trimodality therapy (TMT), a combination of chemotherapy, surgery, and radiotherapy, which is the standard treatment for aggressive breast cancers. They found TMT use was low among patients with IBC, and decreased as the disease progressed. They also found TMT did not improve survival rates among those with IBC, although it did improve survival rates among patients with non-IBC.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page The URL will go live after the embargo ends

Journal/
conference: JAMA Network Open

Research:Paper

Organisation/s: Dana-Farber Cancer Institute, USA

Funder: Dr Lynce provided funding to cover open access fees for the accepted manuscript using the Inflammatory Breast Cancer discretionary funds from the Dana-Farber Institute.

Media Contact/s

Contact details are only visible to registered journalists.